Biologics Contract Development and Manufacturing Organizations (CDMOs) provide specialized services that support the development, manufacturing, and commercialization of biologic drugs such as monoclonal antibodies, recombinant proteins, vaccines, and gene therapies. These organizations enable pharmaceutical and biotech companies to outsource complex processes, reducing operational costs and accelerating time-to-market.
As biologics become central to modern therapeutics, CDMOs play a critical role in addressing manufacturing complexity, regulatory compliance, and scalability challenges. From early-stage development to large-scale commercial production, these partners ensure efficiency, flexibility, and reliability across the biologics lifecycle.
According to BIS Research, the global Biologics CDMO market was valued at $27.19 billion in 2024 and is projected to reach $105.36 billion by 2035, growing at a CAGR of 13.59% during the forecast period, reflecting strong demand for outsourced biologics manufacturing solutions.
Download the complete TOC and Request Sample Report
Key Drivers:
• Growing global demand for biologic therapies, including monoclonal antibodies, vaccines, and gene therapies
• Increasing prevalence of chronic and rare diseases driving adoption of biologics
• Rising R&D investments and funding in biopharmaceutical innovation
• Strategic shift toward outsourcing to optimize cost structures and reduce operational risks
• Advancements in cell line development, process engineering, and scalable manufacturing platforms
According to Principal Analyst at BIS Research:
“The biologics CDMO market is entering a high-growth phase driven by the increasing complexity of biologic drugs and the need for specialized manufacturing capabilities. As pharmaceutical companies continue to outsource across the product lifecycle, CDMOs that offer integrated, scalable, and regulatory-compliant solutions will gain a competitive edge. The shift toward advanced therapies and personalized medicine will further accelerate demand for flexible and high-capacity manufacturing platforms.”
What is the expected growth outlook?
The biologics CDMO market is expected to grow at a CAGR of 13.59%, reaching $105.36 billion by 2035, driven by strong demand for biologics and increasing outsourcing trends.
Who are the key leaders in this market?
Key players include Lonza, Catalent, Inc., Samsung Biologics, Thermo Fisher Scientific, Inc., WuXi Biologics, Boehringer Ingelheim GmbH, and Charles River Laboratories.
Which biologics segments are most in demand?
Monoclonal antibodies dominate the market, particularly in oncology and autoimmune treatments, supported by mammalian expression systems for complex biologic production.
Want to Make Data-Backed Moves in the Biologics CDMO Market?
BIS Research provides expert-driven insights, granular segmentation, and strategic advisory across pharmaceuticals, biotechnology, and advanced healthcare markets.
Request a Sample Report
Book a Preview
Download the complete TOC
